Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement unless cost-effectiveness can be improved relative to existing treatments.
The NCPE recommends that Sativex® not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that nintedanib (Ofev®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*
The Beneluxa collaboration has issued a joint statement with the Nordic Pharmaceutical Forum.
The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that neratinib (Nerlynx®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that Onasemnogene abeparvovec (Zolgensma®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*
Version 2.0 of this template replaces version 1.5. Rapid review submissions using version 1.5 will not be accepted after 31 March 2021. Please send the completed form by email to ncpe@stjames.ie.
Latest Updates…